Pharmaceutical Business Review
Return to: PBR Home

News

View news from other Pharmaceutical sectors:
1-15 of 51317 results
Report says smart pills will gain grounds in diagnostics and health monitoring applications
A report from Persistence Market Research has revealed that increasing uptake for indigestible medical devices will drive global demand for smart pills during 2017 to 2026.
Drug Research > Drug Discovery & Development > News
Novacap to acquire US-based CDMO PCI Synthesis
Novacap has agreed to acquire Boston-based PCI Synthesis, a pharmaceutical contract development and manufacturing organization (CDMO), for an undisclosed price.
Drug Research > Drug Delivery > News
Novo Nordisk’s semaglutide succeeds in two phase 3a type 2 diabetes trials
By PBR Staff Writer
Novo Nordisk said that oral semaglutide succeeded in two phase 3a trials by registering statistically significantly greater reductions in HbA1c and weight in adults with type 2 diabetes.
Contract Research & Services > Clinical Trials > News
Alexion seeks approval from FDA for PNH drug ALXN1210
Alexion Pharmaceuticals said that it has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA), seeking approval for its C5 complement inhibitor ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).
Production & Manufacturing > Process & Production > News
Decibel Therapeutics raises $55m in new funding round
Decibel Therapeutics, a company focused on the discovery and development of medicines to treat hearing loss and hearing-related disorders, has raised $55m in a Series C financing.
Drug Research > Drug Discovery & Development > News
Can-Fite delays phase 2 trial of liver cancer drug Namodenoson
By PBR Staff Writer
Israeli biotechnology company Can-Fite BioPharma revealed that the results of its phase 2 trial of its liver cancer drug Namodenoson (CF102) will be delayed longer than originally estimated.
Contract Research & Services > Clinical Trials > News
£56m medicines manufacturing innovation center to be established in Scotland
By PBR Staff Writer
A new £56m medicines manufacturing innovation center (MMIC) is to be established in Renfrewshire, Scotland, to offer businesses support to transform processes and technologies.
Drug Research > Drug Discovery & Development > News
NeuroVive grants LHON therapy license to BridgeBio Pharma
NeuroVive Pharmaceutical has granted exclusive license of a subset of succinate prodrug chemistry under its NVP015 program to BridgeBio Pharma.
Drug Research > Drug Discovery & Development > News
ImmunoGen gets FDA fast track status for mirvetuximab soravtansine to treat platinum-resistant ovarian cancer
ImmunoGen has secured fast track designation from the US Food and Drug Administration (FDA) for its lead program, mirvetuximab soravtansine.
Regulatory Affairs > News
Sanofi agrees to license infectious disease assets to Evotec
By PBR Staff Writer
Evotec has signed an agreement to integrate Sanofi’s infectious disease unit into its fold as part of a move to create an infectious disease open innovation research and development (R&D) platform in France.
Drug Research > Drug Discovery & Development > News
X4P-001-RD demonstrates promising activity in WHIM syndrome patients
By PBR Staff Writer
X4 Pharmaceuticals said that its X4P-001-RD has demonstrated promising activity in the ongoing open-label phase 2 portion of a phase 2/3 study in patients with WHIM syndrome.
Contract Research & Services > Clinical Trials > News
Celltrion resubmits aBLA to FDA for proposed Trastuzumab biosimilar
South Korea-based Celltrion said that it has completed a re-submission to the US Food and Drug Administration (FDA) seeking approval for CT-P6, a proposed mAb biosimilar to cancer drug Herceptin (trastuzumab).
Production & Manufacturing > Process & Production > News
BMS’ elotuzumab / pomalidomide improves progression-free survival in cancer trial
Bristol-Myers Squibb (BMS) has announced that the ELOQUENT-3 trial, an international Phase 2 study evaluating the addition of Empliciti (elotuzumab) to pomalidomide and low-dose dexamethasone (EPd) in patients with relapsed/refractory multiple myeloma (RRMM), achieved its primary endpoint.
Contract Research & Services > Clinical Trials > News
Futility forces Teva to halt fremanezumab’s chronic cluster headache study
By PBR Staff Writer
Israel-based Teva Pharmaceutical Industries said that it will stop an ongoing phase 3 trial of its migraine drug fremanezumab for the treatment of chronic cluster headache due to futility.
Contract Research & Services > Clinical Trials > News
Faron Pharmaceuticals reports inconsistent Traumakine biomarker results
Faron Pharmaceuticals has announced preliminary biomarker data from its Phase III INTEREST trial of Traumakine for the treatment of Acute Respiratory Distress Syndrome (ARDS).
Contract Research & Services > Clinical Trials > News
1-15 of 51317 results